These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 18061963)

  • 1. Longterm treatment benefits are best reflected by patient reported outcomes.
    Strand CV; Crawford B
    J Rheumatol; 2007 Dec; 34(12):2317-9. PubMed ID: 18061963
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of rheumatoid arthritis with adalimumab. Results from a Cochrane review].
    Pedersen SJ; Hetland ML; Østergaard M
    Ugeskr Laeger; 2006 Aug; 168(35):2899-903. PubMed ID: 16982019
    [No Abstract]   [Full Text] [Related]  

  • 3. Worse patient VAS occurs at weeks 7 and 8 after infliximab infusions.
    Shenker N; Haigh R; Clarke A
    Ann Rheum Dis; 2005 Mar; 64(3):502-3. PubMed ID: 15708905
    [No Abstract]   [Full Text] [Related]  

  • 4. [Danish data document therapeutic effect differences of tumor necrosis factor inhibitors in patient with rheumatoid arthritis].
    Hetland ML
    Ugeskr Laeger; 2010 Jun; 172(26):2003; author reply 2003-4. PubMed ID: 20681045
    [No Abstract]   [Full Text] [Related]  

  • 5. Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis.
    Mittendorf T; Dietz B; Sterz R; Kupper H; Cifaldi MA; von der Schulenburg JM
    J Rheumatol; 2007 Dec; 34(12):2343-50. PubMed ID: 17918788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab therapy in rheumatoid arthritis.
    Keystone E; Haraoui B
    Rheum Dis Clin North Am; 2004 May; 30(2):349-64, vii. PubMed ID: 15172045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment, management, and monitoring of established rheumatoid arthritis.
    Bingham CO; Miner MM
    J Fam Pract; 2007 Oct; 56(10 Suppl Rapid):S1-7; quiz S8. PubMed ID: 17949607
    [No Abstract]   [Full Text] [Related]  

  • 9. [Adalimumab slows the progression of rheumatoid arthritis].
    Pharm Unserer Zeit; 2003; 32(1):75-6. PubMed ID: 12577764
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant DNA product for rheumatoid arthritis.
    FDA Consum; 2003; 37(2):5. PubMed ID: 12715755
    [No Abstract]   [Full Text] [Related]  

  • 11. Adalimumab for rheumatoid arthritis?
    Ebell M; Kripke C
    Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
    [No Abstract]   [Full Text] [Related]  

  • 12. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 13. Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial.
    Pope JE; Thorne C; Haraoui BP; Truong D; Psaradellis E; Sampalis JS
    Scand J Rheumatol; 2011 May; 40(3):232-3. PubMed ID: 21108544
    [No Abstract]   [Full Text] [Related]  

  • 14. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hasty dead certain conclusions about TNF inhibitors].
    Lindberg M
    Ugeskr Laeger; 2010 Nov; 172(45):3125; author reply 3125. PubMed ID: 21105205
    [No Abstract]   [Full Text] [Related]  

  • 16. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheumatoid arthritis.
    Burchini G; Orsi C
    N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
    [No Abstract]   [Full Text] [Related]  

  • 18. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.
    Pincus T; Yazici Y; van Vollenhoven R
    J Rheumatol; 2006 Dec; 33(12):2372-5. PubMed ID: 17143975
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 20. [Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis].
    Zündorf I; Dingermann T
    Pharm Unserer Zeit; 2003; 32(5):376-83. PubMed ID: 14526457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.